Gonzalez, H.L.d.M., et al. Efficacy of LaAg Vaccine Associated with Saponin Against Leishmania amazonensis Infection.
The study evaluated different vaccine formulations incorporating Leishmania amazonensis antigens (LaAg) combined with various adjuvants, including complete Freund’s adjuv...
Read More
Venkatraman, N., et al. R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
The study evaluates the efficacy and safety of the R21 malaria vaccine candidate (Jenner Institute, University of Oxford) formulated with the Matrix-M adjuvant (Novavax) ...
Read More
Ramezani-Rad, .P, et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in non-human primates.
The use of an appropriate adjuvant is crucial for developing an effective HIV vaccine. This study investigates the efficacy of QS-21-based saponin/monophosphoryl lipid A ...
Read More
Zhu, Q., et al. Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy.
The article explores the promising role of phytochemicals, particularly saponins like Quil A and its derivative QS-21 from Quillaja saponaria, in enhancing cancer immunot...
Read More
Gaspar, E.B., et al. Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum.
Bovine colostrum has the potential to serve as a source of neutralizing antibodies for preventing viral infections due to the evolutionary homology between bovine and hum...
Read More
Hickey, J., et al. Two recombinant cytomegalovirus antigens formulated with the SPA14 adjuvant system: Impact of temperature, pH and excipients on the stability of each antigen and adjuvant component.
The study evaluated the stability of two recombinant Cytomegalovirus antigens (gB and Pentamer) formulated with the SPA14 adjuvant system, a liposomal formulation contain...
Read More
Desert King® and the Vaccine Formulation Institute: A Strategic Alliance for Global Access to Vaccine Adjuvants
Desert King® (DK) and the Vaccine Formulation Institute (VFI) have joined forces in a strategic alliance to revolutionize global access to vaccine adjuvants.
Read More
Desert King® achieves EXCiPACT™ certification and strengthens its leadership in vaccine adjuvant production
Desert King®, a global leader in the vaccine adjuvant market based on Quillaja saponaria saponins, is proud to announce his EXCiPACT™ certification.
Read More